Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Novel Therapy for Pediatric Angiosarcoma With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

Winer, Lindsey, MD*; Macedo, Francisco I., MD*; Alfawaz, Abdullah, MD*; Sommariva, Antonio, MD; Cecchetto, Giovanni, MD; Podda, Antonello, MD§; Neville, Holly L., MD; Möller, Mecker G., MD, FACS*

Journal of Pediatric Hematology/Oncology: November 2018 - Volume 40 - Issue 8 - p e505–e510
doi: 10.1097/MPH.0000000000001231
Online Articles: Original Articles

The management of pediatric abdominopelvic angiosarcoma remains unclear due to limited clinical experience. Herein, we presented the first 2 pediatric patients with abdominal angiosarcoma who were treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) after neoadjuvant therapy. The first patient is alive with recurrent disease at 1-year follow-up and the second patient remains disease free after 1 year. CRS and HIPEC should be considered as a therapeutic option in the management of pediatric abdominal angiosarcomas. A multi-institutional international shared registry is needed to further evaluate the role of CRS and HIPEC in inducing remission of abdominopelvic angiosarcomas in the pediatric population.

*Division of Surgical Oncology

§Hematology Oncology

Pediatric Surgery, Jackson Memorial Hospital, University of Miami Miller School of Medicine, Miami, FL

Veneto Institute of Oncology, Pediatric Surgical Oncology Unit, Veneto

University Hospital of Padua, Pediatric Surgery Unit, Padua, Italy

The authors declare no conflict of interest.

Reprints: Mecker G. Möller, MD, FACS, 1120 Nw 14th Street, CRB 4th, Miami, FL 33131 (e-mail: mmoller@med.miami.edu).

Received December 21, 2017

Accepted May 1, 2018

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.